Vysis grants diagnostics licence to bioMerieux:
This article was originally published in Clinica
French company bioMerieux' US subsidiary has taken a non-exclusive licence to use disputed nucleic acid diagnostic technology owned by Vysis under the Collins patent. Another licensee, Gen-Probe has successfully challenged Vysis' patent in relation to blood collection, claiming invalidity. Vysis is appealing the decision.